MedTrace Logo

Protective Monocytes and Macrophages to Limit Decompensation and Heart Damaging

NCT04022330 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-07-25

No results posted yet for this study

Summary

The working hypothesis is that cardiac macrophages specific for the compensated cardiac hypertrophic phase limit the progression toward the decompensated state of heart failure by promoting an inflammatory environment favouring cardiomyocyte survival and preservation of the pump function. The investigators will perform studies in human plasma and monos, cardiac tissues and macrophages to validate this hypothesis.

Conditions

  • Left Ventricular Hypertrophy

Interventions

OTHER

Blood sampling

The blood sampling will be done just before surgery

Sponsors & Collaborators

  • Institute of Cardiometabolism and Nutrition, France

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Reza TAVAKOLI, Dr · Pitié-Salpêtrière Hospital (AP-HP)

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-15
Primary Completion
2023-04-15
Completion
2024-04-15

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04022330 on ClinicalTrials.gov